Cardiovascular – Renal Drugs : Antiplatelets and Thrombolytics
OBRIL1 “Brilinta FC tablet” 90 mg/tab
適應症：Brilinta與Aspirin併用，可減少急性冠心症(包括不穩定型心絞痛、非ST段上升型心肌梗塞或ST段上升型心肌梗塞)患者之栓塞性心血管事件的發生率。與Clopidogrel相比，Brilinta可以降低心血管死亡、心肌梗塞發生率。於中風事件上，兩者並無差異。對於接受經皮冠狀動脈介入治療者，Brilinta亦可減少支架栓塞的發生。Brilinta與Aspirin併用時，Aspirin維持既量應避免每天超過 100 mg。
Usual dose:
Acute coronary syndrome – Thrombosis; Prophylaxis:
Loading dose, 180 mg orally (FDA dosage)
Maintenance, 90 mg orally twice daily for 1 year after acute coronary syndrome event, then 60 mg twice daily; use with aspirin 75 to 100 mg orally once daily
Duration, continue for at least 12 months; use beyond 12 months may be considered in select patients; discontinuation after 6 months may be considered in patient with newer generation drug-eluting stent and high bleeding risk (guideline dosage).
Concomitant medication, aspirin 81 mg daily (range, 75 to 100 mg/day) (guideline dosage)
Myocardial infarction, History of – Thrombosis; Prophylaxis:
(1 year or more after event) 60 mg orally twice daily in combination with aspirin 75 to 100 mg orally daily.
Percutaneous coronary intervention – Thrombosis; Prophylaxis
Loading dose, 180 mg orally (FDA dosage) with aspirin (usually 325 mg) orally once (guideline dosage).
Maintenance, 90 mg orally twice daily for 1 year after acute coronary syndrome event, then 60 mg twice daily; use with aspirin 75 to 100 mg orally once daily (FDA dosage).
Concomitant medication, aspirin 81 mg orally daily (range, 75 to 100 mg/day) (guideline dosage).
Duration (acute coronary syndrome with stent placement), at least 12 months; may continue beyond 12 months in select patients; may consider discontinuation after 6 months in patient with newer generation drug-eluting stent and high bleeding risk (guideline dosage).
Contraindications:
Hypersensitivity (eg, angioedema) to ticagrelor or any product component.
Intracranial hemorrhage, history of pathological bleeding, active (eg, peptic ulcer or intracranial hemorrhage)
Adverse Effects
Common: bleeding, major and minor serum creatinine raised , dyspnea.
Serious: bleeding, major pulmonary hemorrhage.
健保使用規範：(102/7/1)
限用於已發作之急性冠心症(包括不穩定型心絞痛、非ST段上升型心肌梗塞或ST段上升型心肌梗塞)而住院的病人時，得與acetylsalicylic acid (如Aspirin) 合併治療，最長9個月。需於病歷註明住院時間。